Candriam S.C.A. Boosts Stake in Ultragenyx Pharmaceutical Inc. $RARE

Candriam S.C.A. increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 43.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 754,714 shares of the biopharmaceutical company’s stock after purchasing an additional 228,447 shares during the quarter. Candriam S.C.A. owned approximately 0.78% of Ultragenyx Pharmaceutical worth $22,702,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Elevation Point Wealth Partners LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at $55,000. Smartleaf Asset Management LLC boosted its stake in Ultragenyx Pharmaceutical by 205.4% during the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 1,169 shares in the last quarter. Covestor Ltd grew its holdings in Ultragenyx Pharmaceutical by 26.0% in the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 369 shares during the period. CWM LLC grew its holdings in Ultragenyx Pharmaceutical by 1,171.2% in the second quarter. CWM LLC now owns 4,144 shares of the biopharmaceutical company’s stock worth $151,000 after purchasing an additional 3,818 shares during the period. Finally, Osaic Holdings Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 4,371.7% during the second quarter. Osaic Holdings Inc. now owns 4,740 shares of the biopharmaceutical company’s stock valued at $172,000 after purchasing an additional 4,634 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

RARE has been the topic of a number of analyst reports. Leerink Partners dropped their price target on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 30th. Barclays dropped their target price on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, November 24th. Bank of America reduced their price target on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating for the company in a report on Friday, January 2nd. Jefferies Financial Group dropped their price target on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a research note on Tuesday, December 30th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, February 3rd. Sixteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $72.29.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ:RARE opened at $23.88 on Tuesday. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of -4.02 and a beta of 0.16. The business has a 50-day simple moving average of $27.93 and a two-hundred day simple moving average of $29.89. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $18.41 and a fifty-two week high of $46.27.

Key Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx’s gene therapy shows long‑term efficacy in two Sanfilippo studies — supports durability of clinical benefit and strengthens the therapy’s commercial/clinical case, a medium/long‑term positive for RARE. BioSpace Article
• Neutral Sentiment: Quant snapshot placed Ultragenyx among lagging names in a market buy/sell screen — indicates short‑term positioning flows but not a new company-specific development. MSN Quant Snapshot
• Negative Sentiment: Multiple plaintiff firms have filed or posted notices about a class action covering purchases from Aug 3, 2023 to Dec 26, 2025 and are soliciting lead plaintiffs (lead‑plaintiff deadline April 6, 2026). The surge of filings/solicitations (Rosen Law, Faruqi & Faruqi, Robbins LLP, DJS Law Group, Schall Law Firm, Bronstein Gewirtz & Grossman, etc.) increases legal risk, potential settlement exposure, and creates investor uncertainty/near‑term selling pressure. Links: Rosen Law release Rosen Law, Faruqi & Faruqi notice Faruqi, Robbins LLP reminder Robbins LLP, DJS Law Group notice DJS, Schall Law Firm Schall, Bronstein notice Bronstein.

Insiders Place Their Bets

In other news, CFO Howard Horn sold 3,061 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $23.56, for a total transaction of $72,117.16. Following the transaction, the chief financial officer directly owned 88,935 shares of the company’s stock, valued at $2,095,308.60. This represents a 3.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders have sold 6,227 shares of company stock worth $187,126. 5.50% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.